You are here
EVAS THERAPEUTICS LLC
UEI: N7UMM55RJ7S5
# of Employees: 2
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
Cardioprotection by inhibition of coagulation and inflammation in myocardial infarction
Amount: $299,999.00PROJECT SUMMARY ABSTRACTIschemic heart disease is the leading cause of death worldwide with acute myocardial infarctionMIas the primary culpritIn the USaboutpatients have heart attacks each year and o ...
SBIRPhase I2018Department of Health and Human Services National Institutes of Health -
Novel antithrombotic agents to prevent hemodialysis vascular access failure
Amount: $1,365,616.00DESCRIPTION (provided by applicant): Currently, more than 60 % of end-stage renal diseases patients who require chronic hemodialysis are accessed through a native arteriovenous fistula (AVF) or synthe ...
SBIRPhase II2012Department of Health and Human Services National Institutes of Health -
Pharmacologic treatment of thromboembolism
Amount: $167,481.00DESCRIPTION (provided by applicant): Thromboembolic disorders are major causes of morbidity and mortality in the Western societies. Anticoagulants are pivotal agents in the prevention and treatment of ...
SBIRPhase I2009Department of Health and Human Services National Institutes of Health -
Novel Recombinant Anticoagulant Proteins
Amount: $152,652.00DESCRIPTION (provided by applicant): Phase I: Clot formation in the blood vessel (thrombosis) causes a broad range of serious clinical conditions, such as unstable angina, acute myocardial infarction, ...
SBIRPhase I2005Department of Health and Human Services National Institutes of Health